Winkelmann M, Ebeling K, Strohmeyer G, Hottenrott G, Mechl Z, Berges W, Scholten T, Westerhausen M, Schlimok G, Sterz R
Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität Düsseldorf, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1992;118(6):405-7. doi: 10.1007/BF01629421.
In a multicentre study patients with liver metastases stratified to the histology of the primary tumour were investigated. A total of 102 patients with colorectal adenocarcinoma, non-small-cell lung cancer, pancreatic cancer, primary liver carcinoma and malignant melanoma were treated with the thioether lipid ilmofosine. The drug was administered orally as a tablet at a dosage of 150-300 mg/day (75 mg/tablet). The tolerability of ilmofosine was poor. There was a dose-limiting gastrointestinal toxicity with nausea, vomiting and loss of appetite (WHO grade II-IV) in 67% of patients. During the period of therapy (1-29 weeks, 8.5 weeks mean) no complete remission and no partial response were observed. We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies.
在一项多中心研究中，对根据原发性肿瘤组织学进行分层的肝转移患者进行了调查。共有102例患有结直肠癌、非小细胞肺癌、胰腺癌、原发性肝癌和恶性黑色素瘤的患者接受了硫醚脂质 ilmofosine 的治疗。该药物以片剂形式口服给药，剂量为150 - 300毫克/天（75毫克/片）。ilmofosine 的耐受性较差。67%的患者出现了剂量限制性胃肠道毒性，表现为恶心、呕吐和食欲不振（世界卫生组织 II - IV 级）。在治疗期间（1 - 29周，平均8.5周），未观察到完全缓解和部分缓解。因此，我们得出结论，口服 ilmofosine 治疗对因各种恶性肿瘤导致的肝转移患者无效。
